Loading company profile...

Expand full investment commentary ▼

📘 Henry Schein, Inc. (HSIC) — Investment Overview

🧩 Business Model Overview

Henry Schein, Inc. is a leading global provider of health care products and services, primarily servicing dental and medical practitioners, as well as animal health professionals. The company’s core operations revolve around the distribution of dental and medical supplies, equipment, pharmaceuticals, and value-added services. With a vast international footprint, Henry Schein enables independent practices and care providers to access a broad catalog of consumables, diagnostic equipment, digital technologies, and business solutions. Its customer base is diversified, including private practices, large health organizations, alternative care sites, as well as government and institutional buyers.

💰 Revenue Model & Ecosystem

Henry Schein’s revenue streams are multi-dimensional. The company’s foundation lies in the distribution of consumable healthcare supplies and equipment. Complementing this, Henry Schein offers integrated technology solutions, practice management software, and digital workflow tools that are increasingly critical in modern healthcare environments. Ongoing software subscriptions, technical support, financial services, and consulting add additional recurring revenue layers. The company’s scale allows it to manage both enterprise accounts and smaller independent clients, serving both on a transactional and long-term engagement basis. Partnerships with manufacturers and proprietary branding provide additional revenue levers.

🧠 Competitive Advantages

  • Brand strength: Henry Schein is a trusted name recognized by practitioners as a reliable and reputable partner in the healthcare supply chain, with a long history in the sector.
  • Switching costs: Integrated product offerings, digital solutions, and practice management systems create tangible switching costs for customers, embedding Henry Schein into the daily operations of clients.
  • Ecosystem stickiness: The combination of consumables, equipment, digital tools, and value-added services cultivates high customer retention, as practices benefit from bundled solutions and streamlined procurement.
  • Scale + supply chain leverage: Henry Schein’s large-scale operations facilitate strong supplier relationships, operational efficiencies, competitive pricing, and access to exclusive products.

🚀 Growth Drivers Ahead

Several multi-year growth drivers are embedded in Henry Schein’s strategic roadmap. Adoption of digital dentistry and healthcare technologies continues to accelerate, increasing demand for advanced equipment and software offerings. The ongoing shift toward group practices and dental service organizations (DSOs) enhances opportunities for enterprise contracts and bundled solutions. Geographic expansion, particularly in emerging markets, offers a pathway for incremental share gains. Henry Schein is also focused on expanding its suite of data analytics, e-commerce platforms, and clinical workflow tools, positioning it to capture value as healthcare practices modernize. Mergers and acquisitions remain a lever to extend market reach and deepen technological capabilities.

⚠ Risk Factors to Monitor

Henry Schein operates in competitive markets with both global and localized rivals, including specialized distributors and large generalists. Margin pressure is a persistent consideration, particularly as price transparency and online channels gain traction. Regulatory and reimbursement changes in healthcare can affect both demand and compliance costs. Technological disruption — including e-commerce disintermediation or rapid advancements in healthcare delivery — could reshape market dynamics. The company’s international footprint also exposes it to geopolitical, currency, and supply chain risks.

📊 Valuation Perspective

Historically, the market has valued Henry Schein at a level reflecting its sector leadership, recurring revenue profile, and diversified business model, frequently placing it at a premium or in line with other healthcare distributors and service peers. The company’s exposure to both stable consumable revenues and higher-growth digital solutions is seen as balancing defensiveness with upside potential. Perceived execution on digital transformation and margin resilience often influence its comparative valuation.

🔍 Investment Takeaway

The investment thesis for Henry Schein balances the company’s enduring brand, integrated solutions, and global scale against the competitive pressures and evolving dynamics of healthcare distribution. Bulls point to Henry Schein’s ability to capture share in the digital transformation of dental and medical practices, its broad-based ecosystem, and resilient, recurring revenue streams. Bears highlight risks from margin compression, disintermediation by e-commerce channels, and continued regulatory headwinds. Overall, Henry Schein represents a high-quality, strategically positioned operator in a resilient sector, with long-term growth opportunities tied to digitization and global expansion — but ongoing vigilance around competitive, regulatory, and technological risk factors remains warranted.


⚠ AI-generated research summary — not financial advice. Validate using official filings & independent analysis.

📢 Show latest earnings summary

📢 Earnings Summary — HSIC

Henry Schein delivered a solid Q3 with broad-based sales growth across distribution, specialty products, and technology, alongside non-GAAP operating margin expansion. The company is regaining market share in U.S. distribution, saw strong momentum in value implants, and continues to scale its cloud practice management business, now bolstered by an AWS generative AI partnership. Cash generation was healthy, and management accelerated share repurchases with ample remaining authorization. Cost programs and value creation initiatives with KKR are expected to drive over $200 million in operating income improvements over time, supporting the long-term target of high single-digit to low double-digit earnings growth. Near-term headwinds include lower ASPs for digital equipment, medical mix pressures, and ongoing restructuring costs, but the backlog and steady patient traffic support a constructive outlook. Leadership transition remains on track with a CEO successor expected by year-end.

📈 Growth Highlights

  • Total sales $3.3B, up 5.2% YoY (constant currency +4.0%; FX +1.2%; acquisitions +0.7%)
  • Global Distribution & Value-Added Services sales +4.8% YoY
  • U.S. dental merchandise +3.3%; U.S. dental equipment +1.2% with strong double-digit growth in digital equipment volumes
  • U.S. medical distribution +4.7%; Home Solutions +20% reported (+6% ex-acquisitions)
  • International dental merchandise +6.0% reported (+2.5% cc), led by Brazil, Canada, Italy, Spain, Australia
  • International dental equipment +10.1% reported (+5.7% cc), driven by Germany, U.K., Canada, Australia
  • Global Specialty Products Group sales +5.9% reported (+3.9% cc); implants mid-single-digit, value implants double-digit, premium low single-digit
  • International implant sales high single-digit; strong double-digit in DACH and Latin America; U.S. implants low single-digit on tough comp
  • Endodontics mid-single-digit growth; Orthopedics double-digit; Orthodontics stabilized
  • Global Technology Group +9.7% reported (+9.0% cc); practice management software growth high double-digits; cloud customers +20% YoY to 10,500+ Dentrix Ascend and Dentally subscribers

🔨 Business Development

  • Announced partnership with AWS to integrate generative AI into Dentrix Ascend and Dentally (real-time documentation, voice charting, predictive BI, claims validation, dynamic pricing)
  • Phased rollout of new HenrySchein.com Global eCommerce platform in North America; Europe rollout planned for 2026
  • Introduced online financing program supporting U.S. dental equipment growth
  • Acquired controlling interest in a previously held investment (triggered $28M pretax remeasurement gain)
  • KKR strategic partnership amended to allow KKR to increase ownership up to 19.9% via open-market purchases
  • CEO succession process underway; Stanley Bergman to retire as CEO at year-end and remain Chairman; successor expected by year-end
  • Strong order intake at DS World expected to support Q4 equipment sales

💵 Financial Performance

  • GAAP operating margin 4.88% (-6 bps YoY); non-GAAP operating margin 7.83% (+19 bps YoY)
  • Gross margin -56 bps YoY (product mix); sequential decline due to flu vaccine seasonality; U.S. dental distribution gross margin stabilized
  • Non-GAAP effective tax rate 22.9% (vs. 24.9% prior year); Q4 expected 24%–25%
  • GAAP net income $101M ($0.84/diluted share) vs. $99M ($0.78) prior year
  • Non-GAAP net income $167M ($1.38/diluted share) vs. $155M ($1.22) prior year; FX +$0.01 to EPS
  • Pretax remeasurement gain $28M (~$0.23 EPS contribution), higher than $19M in Q3’24
  • Adjusted EBITDA $295M, +10% YoY (vs. $268M)
  • Operating cash flow $174M (vs. $151M Q3’24); expected to exceed net income for full year
  • Accounts receivable increased slightly, consistent with sales growth

🏦 Capital & Funding

  • Repurchased ~3.3M shares for $229M at ~$68.62 avg price in Q3
  • Board increased repurchase authorization by $750M; $980M total remaining at quarter-end
  • Plan to continue buybacks at a similar pace to Q3
  • KKR permitted to increase HSIC ownership up to 19.9%
  • Strong operating cash flow supports capital deployment

🧠 Operations & Strategy

  • BOLD+1 strategy progressing toward >50% of non-GAAP operating income from high-growth, high-margin businesses and >10% from corporate brands by end of 2027
  • Launching multiyear value creation initiatives (centralize support services, indirect procurement, process automation/simplification, accelerate corporate brand sales)
  • Expect >$200M operating income improvement over next few years from value creation programs
  • Restructuring program (announced Aug 2024) targeting >$100M annual run-rate savings; charges to continue in 2026–2027
  • Market share gains in U.S. distribution aided by targeted promotions and corporate brand strength
  • Focus on improving orthodontics profitability; sustained investment in high-growth technology and specialty products

🌍 Market Outlook

  • Patient traffic steady across the quarter
  • U.S. dental equipment growth expected to be maintained in Q4; healthy backlog from DS World order intake
  • Continued strength expected in implants (value segment) and specialty products; positive customer feedback on Tapered Pro Conical (now ~1/3 of U.S. implant sales)
  • Cloud practice management adoption remains strong; recurring SaaS and transactional RCM revenues growing
  • Long-term goal reaffirmed: high single-digit to low double-digit earnings growth
  • Q4 non-GAAP tax rate expected in 24%–25% range
  • Company indicated inability to reasonably estimate certain restructuring costs for detailed guidance at this time

⚠ Risks & Headwinds

  • Lower average selling prices in digital dental equipment despite strong volumes
  • Lower demand for influenza vaccines and respiratory diagnostic products impacting medical mix and gross margin
  • Gross margin pressure from product mix; seasonality in medical products
  • U.S. implant market stable with tough prior-year comparison limiting growth
  • Restructuring charges to continue through 2026–2027
  • Foreign currency fluctuations impacting reported results

AI-generated earnings recap sourced from company results & conference call observations. Not investment advice — verify with official filings.

📊 Henry Schein, Inc. (HSIC) — AI Scoring Summary

📊 AI Stock Rating — Summary

Henry Schein, Inc. reported revenue of $3.24 billion for the quarter ending June 28, 2025, with a net income of $86 million, resulting in an EPS of $0.71. The company's net margin stands at a moderate 2.65%, while it generated a free cash flow of $88 million. Year-over-year growth is muted, reflected in a 4.73% decline in the share price over the past year. Revenue growth appears stable but lacks acceleration, largely driven by its dominant Healthcare Distribution segment. The profitability is moderate with a P/E ratio of 25.97, suggesting the stock might be overvalued relative to earnings. Free cash flow generation remains positive with manageable capital expenditures. With a debt to equity ratio of 0.97, the company has substantial leverage but retains financial stability. Shareholder returns were primarily through stock repurchases, as the company does not pay dividends. Analysts have set price targets as high as $86, indicating potential upside despite recent sideways price trends.

AI Score Breakdown

Revenue Growth — Score: 5/10

Revenue growth is stable, driven by its Healthcare Distribution segment. However, there is little acceleration, and year-over-year growth is restrained.

Profitability — Score: 4/10

Operating margins are modest with a net margin of 2.65% and EPS of $0.71. The P/E ratio of 25.97 indicates possible overvaluation.

Cash Flow Quality — Score: 6/10

Free cash flow is positive and relatively stable at $88 million, with significant stock repurchase activity, indicating a focus on using cash strategically.

Leverage & Balance Sheet — Score: 5/10

The company has a debt to equity ratio of 0.97 and net debt of $3.21 billion. While leverage is noticeable, financial resilience appears adequate.

Shareholder Returns — Score: 5/10

There are no dividends, but active share repurchases are a positive. Share price declined by 4.73% over the past year and increased by 3.88% over the last 6 months, balancing out shareholder return assessment.

Analyst Sentiment & Valuation — Score: 5/10

Analyst targets suggest price may rise to $86. With a P/E ratio of 25.97 and FCF yield of 0.99%, valuation appears stretched, yet sentiment indicates some upside potential.

⚠ AI-generated — informational only, not financial advice.

SEC Filings

Related Companies in Healthcare

SOLV logo

SOLVENTUM CORP (SOLV)

Healthcare

$13.88B

PODD logo

INSULET CORP (PODD)

Healthcare

$19.90B

GEHC logo

GE HEALTHCARE TECHNOLOGIES INC (GEHC)

Healthcare

$38.96B

MOH logo

MOLINA HEALTHCARE INC (MOH)

Healthcare

$10.23B

TECH logo

BIO TECHNE CORP (TECH)

Healthcare

$10.72B

MRNA logo

MODERNA INC (MRNA)

Healthcare

$15.85B